PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Rucaparib (Primary) ; Rucaparib (Primary) ; Cisplatin
- Indications Breast cancer
- Focus Therapeutic Use
- 20 Feb 2018 Planned End Date changed from 1 Oct 2017 to 1 Jun 2018.
- 20 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.
- 31 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History